GlassScriptPhysician profile
Maryum Shoukat
NPI 1619536729
$1,598.44
in general payments reported to CMS, 2019-2025
24 companies · $53.48 in 2025
The $53.48 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $859 · 2024: $686 · 2025: $53.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $164.52 | 2023-2024 | |
| Abbvie INC. | $151.20 | 2023-2025 | Botox, Qulipta |
| Genentech USA, INC. | $137.11 | 2023-2024 | Ocrevus, Enspryng |
| Otsuka America Pharmaceutical, INC. | $129.59 | 2023-2024 | Rexulti, Nuedexta |
| Novo Nordisk INC | $128.78 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Neurelis, INC. | $115.53 | 2023-2024 | Valtoco |
| Neurocrine Biosciences, INC. | $102.16 | 2023-2024 | Ingrezza |
| Sumitomo Pharma America, INC. | $80.15 | 2023-2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $72.69 | 2023-2024 | Trintellix, Entyvio |
| Teva Pharmaceuticals USA, INC. | $69.47 | 2023-2024 | Austedo Xr |
| Philips North America LLC | $57.15 | 2023-2025 | Vest Therapy Und |
| Astellas Pharma US INC | $55.19 | 2023-2024 | Veozah |
| Corium, LLC | $51.00 | 2023 | Adlarity |
| Amgen INC. | $43.65 | 2023 | Prolia, Evenity, Otezla |
| Ucb, INC. | $37.21 | 2024 | Briviact, Nayzilam |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.93 | 2024 | Jardiance, Zepbound |
| Exact Sciences Corporation | $28.33 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $24.23 | 2024 | Auvelity |
| Dexcom, INC. | $24.19 | 2023 | Dexcom G6 Transmitter |
| Alkermes, INC. | $23.92 | 2023 | Aristada, Lybalvi |
| Nestle Healthcare Nutrition INC. | $21.16 | 2023 | |
| Merck Sharp & Dohme LLC | $17.10 | 2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $14.14 | 2023 | |
| Baxter Healthcare | $14.04 | 2024 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryum Shoukat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.